Business
Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions at 63rd ASH Annual Meeting
- Robust clinical activity with durable responses and no discontinuations due to treatment-related adverse events observed in Phase 1 portion of AUGMENT-101
About this update from Syndax Pharmaceuticals, Inc.
[{"type":"text","content":"- Robust clinical activity with durable responses and no discontinuations due to treatment-related adverse events observed in Phase 1 portion of AUGMENT-101 trial of SNDX-5613 in relapsed or refractory patients with genetically-defined acute leukemias -\n - Phase 2 results highlight broad efficacy and tolerability of axatilimab at 1mg/kg in patients with relapsed or refractory cGVHD -\n\n\nWALTHAM, Mass., Nov. 4, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that updated data from both of its ongoing SNDX-5613 and axatilimab programs will be featured during oral sessions at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 11-14, 2021. SNDX-5613 is the Company's highly selective oral menin inhibitor. Axatilimab is Syndax's anti-CSF-1R monoclonal antibody.\n\"We are pleased to share that both our innovative pipeline programs will be highlighted during oral presentation sessions at the upcoming ASH Annual Meeting,\" said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax. \"For SNDX-5613, updated data from the Phase 1 portion of AUGMENT-101 continue to demonstrate robust clinical activity and a well-tolerated safety profile in heavily pretreated patients with mixed lineage leukemia rearranged (MLLr) or nucleophosmin (NPM1c) mutations.\"\n\"We are also excited to share updates from the Phase 1/2 trial of axatilimab for the treatment of chronic graft-versus-host disease (cGVHD). With additional patients and longer follow up, we have observed a high rate of durable responses and multiorgan clinical benefit in patients refractory to multiple therapeutic agents. We are encouraged by the continued trend we are seeing, notably in those treated in the 1 mg/kg Phase 2 expansion cohort, and look forward to presenting additional updated data for both programs in December.\"\nSNDX-5613\nA copy of the abstract published today can be viewed here. The oral presentation will include updated Phase 1 data from additional patients as of a more recent cutoff date, as well as further details on durability and complete response (CR) or CR with partial hematologic recovery (CRh) rate and mutational status.\nThe abstract highlights data from the Phase 1 portion of the ...